GLPwatch
Papers (10389)
Page 164 of 174, ranked by citation count.
- GIPR:GCGR co-agonism restores normal weight in obese rodents.
- Comparative Effectiveness and Safety of Once-Weekly Injectable Semaglutide Versus Dulaglutide in Individuals with Type 2 Diabetes Managed in UK Primary Care: A Population-Based Cohort Study.
- [Not Available].
- Dynamic structural analysis-based epitope prediction of Exendin-4 in aqueous solution.
- Improving sensitivity and drug tolerance of assays for neutralizing anti-drug antibodies to semaglutide and native GLP-1.
- Liraglutide in diabetes mellitus: More facts and findings.
- Enhancing economic modelling in obesity: integrating novel type 2 diabetes progression & obstructive sleep apnea remission - a UK case study.
- Non-arteritic anterior ischaemic optic neuropathy incidence in placebo-controlled clinical trials of liraglutide or semaglutide.
- Glycemic Improvement with Low-Dose Dulaglutide Is Associated with Leptin and Obestatin Modulation in Type 2 Diabetes Mellitus.
- Comparative Efficacy of Tirzepatide vs Semaglutide on Liver and Cardiovascular Related Outcomes in Patients with MASLD/MASH, Obesity, and Type 2 Diabetes Mellitus: A Real-World Cohort Study.
- Pharmacotherapy for obesity management.
- Cardiorenal Safety Markers With Injectable Glucagon-Like Peptide-1 (GLP-1) Agonists in Type 2 Diabetes: A Network Meta-Analysis.
- Semaglutide (Wegovy) for weight loss.
- Digital multicriteria evaluation of negotiated medicines using Chinese mini-HTA: application of structured methodologies in assessing once-weekly GLP-1 RAs for improved clinical decision-making.
- Incretin-Based Therapies and Heart Failure Outcomes: Benefit Beyond Weight Loss?
- Severe Euglycemic Ketoacidosis Secondary to Tirzepatide Use for Weight Loss.
- Survodutide: a novel peptide for treatment of obesity and metabolic diseases.
- Reversion to normoglycemia with tirzepatide vs semaglutide in participants with obesity and prediabetes: a post hoc analysis of SURMOUNT-5.
- [Glucagon-like peptide-1: a cardiological perspective].
- [Indicators of diabetes mellitus after liraglutide, sitagliptin/metformin, linagliptin, and sitagliptin].
- Nmnat2 deficiency in the arcuate nucleus or paraventricular nucleus induces Sarm1-independent neuron loss and liraglutide-reversible obesity.
- Integrative proteogenomic analyses implicate KLK13 as a glycaemia-linked circulating protein in diabetic kidney disease.
- Optimized sublingual delivery of dual fatty acid-conjugated GLP-1 receptor agonist TE-8105 produces durable efficacy in diabetic mice.
- Recommendation for Clarifying FDA Policy in Evaluating "Sameness" of Higher Order Structure for Generic Peptide Therapeutics.
- Incretin effect is sufficient for glucose control in developing rats.
- Clinical outcomes of glucagon-like peptide-1 receptor agonist therapy in kidney transplant recipients: a systematic review and meta-analysis.
- Semaglutide vs Tirzepatide Dosages for Weight Loss-Reply.
- Cost-effectiveness of incretin therapies: a Canadian lens on diabetes, obesity, and emerging indications.
- The role of dulaglutide in the treatment of alcohol use disorder: a case report.
- Liraglutid verzögert Diabetesentstehung.
- Experience with dulaglutide in a diabetic and obese patient on incremental peritoneal dialysis.
- Liraglutide, a GLP-1 Receptor Agonist, Mitigates LPS-Induced Osteoclastogenesis and Bone Loss by Downregulating Macrophage TNF-α Expression.
- Response to "Experience with dulaglutide in an obese diabetic patient on incremental peritoneal dialysis". Response to related letter.
- Glucagon-Like Peptide-1 Receptor Agonists: Their Therapeutic Potential in Cystic Fibrosis.
- From Glycemic Control to Weight-Centered Therapy: A Paradigm Shift in Type 2 Diabetes and Its Public Health Promise.
- Comparison table: Some FDA-approved drugs for weight management.
- Variables associated with insulin production in persons with type 2 diabetes treated with multiple daily insulin injections.
- Tirzepatide for Recurrent Weight Gain after Bariatric Procedures: Real-World Evidence of Efficacy and Safety.
- Safety of iGlarLixi in Japanese People with Type 2 Diabetes: A Post-marketing Database Study.
- Effect of tirzepatide on prediabetics and blood pressure with implications for future research.
- Major adverse cardiovascular and limb events caused by tirzepatide in patients with type 2 diabetes at high cardiovascular risk: A comparison with sitagliptin.
- The association between glucagon-like peptide-1 receptor agonist and rheumatoid arthritis: a population-based case-control study.
- [A meta-analysis of efficacy and safety of anti-obesity medications in the treatment of childhood obesity].
- Glycemic and Economic Outcomes in Elderly Patients with Type 2 Diabetes Initiating Dulaglutide Versus Basal Insulin in a Real-World Setting in the United States: The DISPEL-Advance Study.
- Use of second-generation incretin analogs (GLP-1 and GIP receptor agonists) in type 1 diabetes and latent autoimmune diabetes in adults: A systematic review.
- Pharmacological progress in obesity: tirzepatide's rising advantage over semaglutide.
- Aggregation-driven expression of liraglutide precursors using engineered mini-tags in Escherichia coli.
- Glucagon-like peptide-1 agonists in children with obesity and type 2 diabetes. an umbrella review.
- JPEN Journal Club 88. Determining the hypothesis of a study.
- [Twice-daily and weekly exenatide: Clinical profile of two pioneer formulations in incretin therapy].
- 1-year outcomes of semaglutide, tirzepatide, and sleeve gastrectomy in obesity in type 2 diabetes: a retrospective cohort study.
- GLP-1 receptor agonist adjunct therapy stabilises Ramadan dysglycaemia in insulin-treated diabetes: a CGM-based study.
- In early T2D inadequately controlled with diet and exercise, once-daily orforglipron reduced HbA<sub>1c</sub> vs. placebo at 40 wk.
- Selective amylin receptor agonism: promise beyond incretins.
- Cardiovascular outcomes of semaglutide and tirzepatide in type 2 diabetes mellitus and obesity: a systematic review and meta-analysis.
- Glucagon-like Peptide-1 Receptor Agonists as a Dual-target Strategy for Depression and Metabolic Health: A Narrative Review.
- Currently Approved and Future Regimens for Metabolic Dysfunction-Associated Steatohepatitis.
- Glucagon-like peptide-1 receptor analogues and beyond: emerging obesity pharmacotherapies.
- Drugs for chronic heart failure.
- Tirzepatide in Obesity-Related Obstructive Sleep Apnea: Beyond Weight Loss Toward Disease Modification?